<SEC-DOCUMENT>0001213900-23-025868.txt : 20230403
<SEC-HEADER>0001213900-23-025868.hdr.sgml : 20230403
<ACCEPTANCE-DATETIME>20230403080502
ACCESSION NUMBER:		0001213900-23-025868
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20230403
FILED AS OF DATE:		20230403
DATE AS OF CHANGE:		20230403

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Enlivex Therapeutics Ltd.
		CENTRAL INDEX KEY:			0001596812
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36578
		FILM NUMBER:		23790694

	BUSINESS ADDRESS:	
		STREET 1:		37 DEREH MENACHEM BEGIN ST.
		STREET 2:		15TH FLOOR
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6522042
		BUSINESS PHONE:		972 (0) 3 7326616

	MAIL ADDRESS:	
		STREET 1:		37 DEREH MENACHEM BEGIN ST.
		STREET 2:		15TH FLOOR
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6522042

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Bioblast Pharma Ltd.
		DATE OF NAME CHANGE:	20160919

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIO BLAST PHARMA LTD.
		DATE OF NAME CHANGE:	20140113
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea176303-6k_enlivex.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">UNITED STATES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 6-K</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Report of Foreign Private Issuer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Pursuant to Rule 13a-16 or 15d-16</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">under the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the month of: April 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission file number: 001-36578</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>ENLIVEX THERAPEUTICS LTD.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Translation of registrant&rsquo;s name into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>14 Einstein Street, Nes Ziona, Israel 7403618</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 20-F&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form
40-F&nbsp;&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On April 3, 2023, Enlivex Therapeutics Ltd., a
company organized under the laws of the State of Israel, issued a press release announcing a clinical collaboration with BeiGene. to evaluate
the safety and efficacy of Allocetra&trade;, an investigational macrophage-reprogramming cell therapy, in combination with tislelizumab,
an anti-PD-1 immune checkpoint inhibitor, for the treatment of patients with advanced-stage solid tumors. A copy of such press release
is furnished as Exhibit 99.1 to this Report on Form 6-K and incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    No.</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="width: 90%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea176303ex99-1_enlivex.htm">Press Release issued by Enlivex Therapeutics Ltd. on April 3, 2023.</A></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SIGNATURES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enlivex Therapeutics Ltd.</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant)</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 35%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Oren Hershkovitz</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Name:&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Title:</P></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oren Hershkovitz<BR>
Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: April 3, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">2</FONT><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea176303ex99-1_enlivex.htm
<DESCRIPTION>PRESS RELEASE ISSUED BY ENLIVEX THERAPEUTICS LTD. ON APRIL 3, 2023
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><IMG SRC="ex99-1_001.jpg" ALT="">&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt">Enlivex
Announces Clinical Collaboration to Evaluate Combinations of Allocetra and PD-1 Inhibitor Tislelizumab for Patients with Solid Tumors</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nes-Ziona,
Israel, April 3, 2023 (GLOBE NEWSWIRE) &ndash; </FONT>Enlivex Therapeutics Ltd. (Nasdaq: ENLV, &ldquo;Enlivex&rdquo;), a
clinical-stage macrophage reprogramming immunotherapy company, today announced a clinical collaboration with BeiGene. to evaluate
the safety and efficacy of Allocetra&trade;, an investigational macrophage-reprogramming cell therapy, in combination with
tislelizumab, an anti-PD-1 immune checkpoint inhibitor, for the treatment of patients with advanced-stage solid tumors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;We
are excited to explore the potential of Allocetra in combination with tislelizumab, a potentially differentiated PD-1 inhibitor,&rdquo;
said Shai Novik, Executive Chairman of Enlivex. &ldquo;We look forward to integrating tislelizumab into our ongoing Phase I/II clinical
trial.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Combinatorial
approaches for fighting difficult-to-treat cancers historically have proven to be important in the delivery of better treatments to patients&rdquo;,
said Oren Hershkovitz, Ph.D., CEO of Enlivex. &ldquo;We believe that the preclinical data observed to date for Allocetra, with its unique
macrophage-modulation properties, and immune checkpoints, support the evaluation of the combination for the treatment of patients with
the tislelizumab-Allocetra combinations.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms of the clinical collaboration agreement, Enlivex has agreed to amend its ongoing Phase I/II trial in patients with advanced-stage
solid tumors to include evaluation of Allocetra in combination with tislelizumab. The Phase I/II trial is a multicenter, open-label,
dose escalation trial that is expected to enroll up to 48 patients with advanced solid tumors across two trial stages. Stage 1 of the
trial will examine escalating doses of Allocetra&trade; monotherapy administered intravenously (IV) or intraperitoneally (IP) once a
week for three consecutive weeks. Stage 2 will evaluate escalating doses of Allocetra administered IV or IP and combined with anti-PD1
therapy. BeiGene will provide the clinical supply of tislelizumab for the trial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ABOUT
TISLELIZUMAB</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tislelizumab
(BGB-A317) is a humanized IgG4 anti&ndash;PD-1 monoclonal antibody specifically designed to minimize binding to Fc&gamma;R on macrophages.
In pre-clinical studies, binding to Fc&gamma;R on macrophages has been shown to compromise the anti-tumor activity of PD-1 antibodies
through activation of antibody-dependent macrophage-mediated killing of T effector cells. Tislelizumab is being developed as a monotherapy
and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ABOUT
ALLOCETRA&trade;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allocetra&trade;
is being developed as a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Diseases
such as solid cancers, sepsis, and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages
contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, Allocetra has the potential
to provide a novel immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as &ldquo;unmet medical
needs&rdquo;, as a stand-alone therapy or in combination with leading therapeutic agents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ABOUT
ENLIVEX</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enlivex
is a clinical stage macrophage reprogramming immunotherapy company developing Allocetra&trade;, a universal, off-the-shelf cell therapy
designed to reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is
critical for immune system rebalancing and resolution of life-threatening conditions. For more information, visit &nbsp;http://www.enlivex.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Safe
Harbor Statement:&nbsp; This press release contains forward-looking statements, which may be identified by words such as &ldquo;expects,&rdquo;
&ldquo;plans,&rdquo; &ldquo;projects,&rdquo; &ldquo;will,&rdquo; &ldquo;may,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;believes,&rdquo;
&ldquo;should,&rdquo; &ldquo;would&rdquo;, &ldquo;could,&rdquo; &ldquo;intends,&rdquo; &ldquo;estimates,&rdquo; &ldquo;suggests,&rdquo;
&ldquo;has the potential to&rdquo; and other words of similar meaning, including statements regarding expected cash balances, market
opportunities for the results of current clinical studies and preclinical experiments, the effectiveness of, and market opportunities
for, ALLOCETRA<SUP>TM</SUP>&nbsp;programs. All such forward-looking statements are made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995.&nbsp; Investors are cautioned that forward-looking statements involve risks and uncertainties
that may affect&nbsp;Enlivex&rsquo;s&nbsp;business and prospects, including the risks that&nbsp;Enlivex&nbsp;may not succeed in generating
any revenues or developing any commercial products; that the products in development may fail, may not achieve the expected results or
effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied
or for other indications; that ongoing studies may not continue to show substantial or any activity; and other risks and uncertainties
that may cause results to differ materially from those set forth in the forward-looking statements. The results of clinical trials in
humans may produce results that differ significantly from the results of clinical and other trials in animals. The results of early-stage
trials may differ significantly from the results of more developed, later-stage trials. The development of any products using the ALLOCETRA<SUP>TM</SUP>&nbsp;product
line could also be affected by&nbsp;a number of&nbsp;other factors, including unexpected safety, efficacy or manufacturing issues, additional
time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive
products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties.&nbsp; In addition
to the risk factors described above, investors should consider the economic, competitive, governmental,&nbsp;technological&nbsp;and other
factors discussed in&nbsp;Enlivex&rsquo;s&nbsp;filings with the Securities and Exchange Commission, including in the Company&rsquo;s
most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission.&nbsp; The forward-looking statements contained
in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking
statements, except as required under applicable law.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ENLIVEX
CONTACT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B>Shachar Shlosberger, CFO</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enlivex Therapeutics, Ltd.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shachar@enlivexpharm.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INVESTOR
RELATIONS CONTACT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B>Eric Ribner</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LifeSci Advisors</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">eric@lifesciadvisors.com</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !^ ,D# 2(  A$! Q$!_\0
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E0@ZE.?.$XS_K..>.G'''3CCBJ5% )6"BBB@L**** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
